Medexus Pharmaceuticals Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kenneth d’Entremont
- Full Time Employees
- 90
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 10 King Street East Toronto ON Canada M5C 1C3
- IPO Date
- Mar 3, 2012
- Website
- medexus.com
- Similar Companies
- Business
- Medexus Pharmaceuticals Inc. (TSX:MDP) operates as a leading innovative specialty pharmaceutical company focused on the commercialization of treatments in hematology-oncology, rheumatology, allergy, dermatology, and rare diseases across North America. The company offers a portfolio of branded products including Rasuvo and Metoject, subcutaneous methotrexate injections for autoimmune disorders such as rheumatoid arthritis; IXINITY, a recombinant factor IX therapy for hemophilia B; Rupall, an allergy medication; Gleolan, an imaging agent for oncology applications; and GRAFAPEX (treosulfan) for injection, a conditioning treatment for allogeneic hematopoietic stem cell transplantation launched in February 2025. It conducts commercial operations in Canada and the United States through a fully integrated platform encompassing salesforce, supply chain, regulatory affairs, and medical support. Founded in 2003 and headquartered in Toronto, Ontario, at 10 King Street East, Suite 600, Medexus targets healthcare providers, specialty pharmacies, and institutions serving patients with complex therapeutic needs. The company, formerly known as Pediapharm Inc., rebranded to Medexus Pharmaceuticals Inc. in December 2018 to reflect its expanded focus on specialty pharmaceuticals. In recent developments, Medexus secures US$51.0 million in new credit facilities from National Bank of Canada in November 2025, comprising a US$21.0 million term loan, US$5.0 million revolving facility, US$10.0 million delayed draw for licensing and acquisitions, and a US$15.0 million uncommitted accordion feature maturing in 2029; it also announces plans for a normal course issuer bid share repurchase program. Earlier in 2025, GRAFAPEX receives U.S. CMS New Technology Add-On Payment approval effective October 2025, providing up to US$21,411 supplemental reimbursement per eligible procedure, and the company raises C$30 million through a public share offering to fund regulatory milestones and growth initiatives. Medexus advances portfolio optimization by terminating U.S. rights to Gleolan in 2025 to prioritize Canadian operations where demand grew 36%, while enhancing IXINITY manufacturing yields and pursuing strategic acquisitions in rare disease areas.
Company News
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Medexus Pharmaceuticals Inc. (MDP:CA) Q2 2026 Earnings Call Transcript
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection